Free Trial
→ Musk’s Project Colossus could mint millionaires (From Brownstone Research) (Ad) Buy RCKTW Stock  Free RCKTW Stock Alerts

Rocket Pharmaceuticals (RCKTW) Financials

Rocket Pharmaceuticals logo
$0.05 0.00 (-1.89%)
Closing price 05/23/2025 03:52 PM Eastern
Extended Trading
$0.04 0.00 (-3.86%)
As of 05/23/2025 04:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Rocket Pharmaceuticals

Annual Income Statements for Rocket Pharmaceuticals

This table shows Rocket Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022
Period end date 12/31/2024 12/31/2023 12/31/2022
Net Income / (Loss) Attributable to Common Shareholders		 -259 -246 -222
Consolidated Net Income / (Loss)		 -259 -246 -222
Net Income / (Loss) Continuing Operations		 -267 -256 -222
Total Pre-Tax Income 		-267 -256 -222
Total Operating Income		 -273 -260 -224
Total Gross Profit		 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00
Operating Revenue		 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00
Total Operating Expenses		 273 260 224
Selling, General & Admin Expense		 102 73 59
Research & Development Expense		 171 186 165
Total Other Income / (Expense), net		 6.38 3.41 2.03
Interest Expense		 1.89 1.88 1.86
Interest & Investment Income		 8.27 5.29 3.89
Other Adjustments to Consolidated Net Income / (Loss)		 8.08 11 -0.05
Basic Earnings per Share		 ($2.73) ($2.92) ($3.26)
Weighted Average Basic Shares Outstanding		 94.81M 84.01M 68.15M
Diluted Earnings per Share		 ($2.73) ($2.92) ($3.26)
Weighted Average Diluted Shares Outstanding		 94.81M 84.01M 68.15M
Weighted Average Basic & Diluted Shares Outstanding		 106.63M 90.50M 79.35M

Quarterly Income Statements for Rocket Pharmaceuticals

This table shows Rocket Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Income / (Loss) Attributable to Common Shareholders		 -61 -60 -67 -70 -62 -60 -62 -66 -58 -67 -58
Consolidated Net Income / (Loss)		 -61 -60 -67 -70 -62 -60 -62 -66 -58 -67 -58
Net Income / (Loss) Continuing Operations		 -64 -62 -69 -72 -65 -63 -64 -68 -61 -68 -58
Total Pre-Tax Income 		-64 -62 -69 -72 -65 -63 -64 -68 -61 -68 -58
Total Operating Income		 -64 -63 -69 -74 -67 -63 -65 -69 -62 -69 -58
Total Gross Profit		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Operating Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 64 63 69 74 67 63 65 69 62 68 59
Selling, General & Admin Expense		 28 25 27 27 22 22 19 17 16 19 15
Research & Development Expense		 36 37 42 46 45 42 47 51 46 50 43
Total Other Income / (Expense), net		 0.86 1.14 0.86 1.82 2.56 0.34 1.25 0.38 1.44 1.35 0.89
Interest Expense		 0.47 0.47 0.47 0.47 0.47 0.47 0.47 0.47 0.47 0.47 0.47
Interest & Investment Income		 1.34 1.62 1.33 2.29 3.03 0.81 1.72 0.85 1.91 1.82 1.35
Other Adjustments to Consolidated Net Income / (Loss)		 2.19 1.22 1.85 2.24 2.76 3.28 2.28 2.68 2.42 - -
Basic Earnings per Share		 ($0.56) ($0.62) ($0.71) ($0.74) ($0.66) ($0.62) ($0.75) ($0.82) ($0.73) ($0.89) ($0.87)
Weighted Average Basic Shares Outstanding		 110.09M 94.81M 94.16M 93.75M 93.55M 84.01M 82.64M 80.47M 79.45M 68.15M 66.22M
Diluted Earnings per Share		 ($0.56) ($0.62) ($0.71) ($0.74) ($0.66) ($0.62) ($0.75) ($0.82) ($0.73) ($0.89) ($0.87)
Weighted Average Diluted Shares Outstanding		 110.09M 94.81M 94.16M 93.75M 93.55M 84.01M 82.64M 80.47M 79.45M 68.15M 66.22M
Weighted Average Basic & Diluted Shares Outstanding		 107.74M 106.63M 91.16M 90.98M 90.78M 90.50M 90.16M 80.53M 80.46M 79.35M 75.68M

Annual Cash Flow Statements for Rocket Pharmaceuticals

This table details how cash moves in and out of Rocket Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022
Period end date 12/31/2024 12/31/2023 12/31/2022
Net Change in Cash & Equivalents		 108 -85 -92
Net Cash From Operating Activities		 -210 -195 -178
Net Cash From Continuing Operating Activities		 -210 -195 -178
Net Income / (Loss) Continuing Operations		 -259 -246 -222
Consolidated Net Income / (Loss)		 -259 -246 -222
Depreciation Expense		 7.22 4.94 3.93
Amortization Expense		 -5.91 -8.01 2.33
Non-Cash Adjustments To Reconcile Net Income		 46 40 32
Changes in Operating Assets and Liabilities, net		 1.74 14 6.02
Net Cash From Investing Activities		 132 -98 -69
Net Cash From Continuing Investing Activities		 132 -98 -69
Purchase of Property, Plant & Equipment		 -5.86 -16 -8.36
Purchase of Investments		 -246 -391 -376
Sale of Property, Plant & Equipment		 0.14 0.00 0.00
Divestitures		 0.00 0.00 43
Sale and/or Maturity of Investments		 383 309 273
Other Investing Activities, net		 0.00 -0.04 -0.26
Net Cash From Financing Activities		 186 208 155
Net Cash From Continuing Financing Activities		 186 208 155
Repurchase of Common Equity		 0.00 0.00 -0.05
Issuance of Common Equity		 183 206 155
Other Financing Activities, net		 3.21 2.24 0.63
Cash Interest Paid		 0.00 0.00 0.00

Quarterly Cash Flow Statements for Rocket Pharmaceuticals

This table details how cash moves in and out of Rocket Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Change in Cash & Equivalents		 -114 98 27 3.33 -21 -170 181 -19 -76 -56 9.13
Net Cash From Operating Activities		 -56 -47 -52 -54 -57 -29 -57 -51 -58 -56 -44
Net Cash From Continuing Operating Activities		 -56 -47 -52 -54 -57 -29 -57 -51 -58 -56 -44
Net Income / (Loss) Continuing Operations		 -61 -60 -67 -70 -62 -60 -62 -66 -58 -67 -58
Consolidated Net Income / (Loss)		 -61 -60 -67 -70 -62 -60 -62 -66 -58 -67 -58
Depreciation Expense		 2.45 1.82 1.85 1.83 1.72 1.40 1.22 1.19 1.14 1.05 1.09
Amortization Expense		 0.54 -0.68 -1.31 -4.46 0.54 -9.63 5.37 -4.29 0.54 -0.40 0.69
Non-Cash Adjustments To Reconcile Net Income		 8.27 13 11 14 7.53 17 4.14 13 6.61 10 7.11
Changes in Operating Assets and Liabilities, net		 -5.73 -0.75 2.78 4.30 -4.59 22 -6.00 5.30 -7.60 0.16 4.41
Net Cash From Investing Activities		 -58 -38 79 56 35 -141 48 31 -37 -109 23
Net Cash From Continuing Investing Activities		 -58 -38 79 56 35 -141 48 31 -37 -109 23
Purchase of Property, Plant & Equipment		 -0.36 -0.31 -1.59 -1.93 -2.04 -4.65 -4.66 -4.12 -3.02 -3.00 -0.50
Purchase of Investments		 -140 -124 -19 -39 -64 -209 -13 -73 -96 -199 -34
Sale and/or Maturity of Investments		 82 86 100 96 101 72 66 108 62 51 58
Other Investing Activities, net		 0.00 - - - 0.00 - - -0.03 -0.01 -0.26 -
Net Cash From Financing Activities		 0.00 183 0.18 1.53 1.18 0.39 189 0.18 18 108 30
Net Cash From Continuing Financing Activities		 0.00 183 0.18 1.53 1.18 0.39 189 0.18 18 108 30
Issuance of Common Equity		 0.00 183 - - 0.00 0.00 189 - 17 108 29
Other Financing Activities, net		 0.00 0.32 0.18 1.53 1.18 0.39 0.55 0.18 1.12 0.32 0.23

Annual Balance Sheets for Rocket Pharmaceuticals

This table presents Rocket Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022
Period end date 12/31/2024 12/31/2023 12/31/2022
Total Assets		 528 566 552
Total Current Assets		 378 378 364
Cash & Equivalents		 164 56 141
Short-Term Investments		 209 317 216
Prepaid Expenses		 5.85 5.05 7.67
Plant, Property, & Equipment, net		 37 39 29
Total Noncurrent Assets		 113 148 159
Long-Term Investments		 0.00 34 43
Noncurrent Note & Lease Receivables		 42 45 47
Goodwill		 39 39 39
Intangible Assets		 25 25 26
Other Noncurrent Operating Assets		 6.06 4.43 3.92
Total Liabilities & Shareholders' Equity		 528 566 552
Total Liabilities		 64 74 62
Total Current Liabilities		 41 49 39
Accounts Payable		 38 46 37
Other Current Liabilities		 2.86 2.72 2.51
Total Noncurrent Liabilities		 24 25 23
Other Noncurrent Operating Liabilities		 24 25 23
Commitments & Contingencies		 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 463 493 490
Total Preferred & Common Equity		 463 493 490
Preferred Stock		 0.00 0.00 0.00
Total Common Equity		 463 493 490
Common Stock		 1,681 1,452 1,204
Retained Earnings		 -1,218 -959 -714
Treasury Stock		 0.00 0.00 -0.05
Accumulated Other Comprehensive Income / (Loss)		 0.07 0.32 -0.36

Quarterly Balance Sheets for Rocket Pharmaceuticals

This table presents Rocket Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q3 2024 Q2 2024 Q1 2024 Q3 2023 Q2 2023 Q1 2023 Q3 2022
Period end date 3/31/2025 9/30/2024 6/30/2024 3/31/2024 9/30/2023 6/30/2023 3/31/2023 9/30/2022
Total Assets		 471 394 446 499 599 462 515 417
Total Current Assets		 324 242 293 345 447 312 338 311
Cash & Equivalents		 50 66 39 35 226 45 65 197
Short-Term Investments		 268 170 240 295 212 262 267 110
Prepaid Expenses		 6.33 6.09 14 15 9.69 5.03 6.95 4.60
Plant, Property, & Equipment, net		 35 39 40 39 37 33 31 26
Total Noncurrent Assets		 112 113 114 115 115 117 146 81
Noncurrent Note & Lease Receivables		 42 43 43 44 45 46 46 47
Goodwill		 39 39 39 39 39 39 39 31
Intangible Assets		 25 25 25 25 25 26 26 -
Other Noncurrent Operating Assets		 5.88 6.21 6.39 6.66 6.00 6.25 6.17 2.83
Total Liabilities & Shareholders' Equity		 471 394 446 499 599 462 515 417
Total Liabilities		 59 64 62 58 58 59 56 50
Total Current Liabilities		 35 40 38 33 33 34 31 30
Accounts Payable		 32 37 35 30 31 31 29 28
Other Current Liabilities		 2.88 2.85 2.86 2.87 2.85 2.99 2.60 2.36
Total Noncurrent Liabilities		 24 24 24 25 24 24 25 20
Other Noncurrent Operating Liabilities		 24 24 24 25 24 24 25 20
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 412 330 385 442 541 403 459 367
Total Preferred & Common Equity		 412 330 385 442 541 403 459 367
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 412 330 385 442 541 403 459 367
Common Stock		 1,692 1,487 1,476 1,463 1,441 1,242 1,231 1,015
Retained Earnings		 -1,279 -1,158 -1,091 -1,021 -900 -838 -772 -647
Accumulated Other Comprehensive Income / (Loss)		 -0.03 0.21 -0.22 -0.14 -0.51 -0.72 -0.09 -0.60

Annual Metrics And Ratios for Rocket Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Rocket Pharmaceuticals' official financial filings.

Metric 2024 2023 2022
Period end date 12/31/2024 12/31/2023 12/31/2022
Growth Metrics		 - - -
Revenue Growth		 0.00% 0.00% 0.00%
EBITDA Growth		 -3.49% -20.48% -37.82%
EBIT Growth		 -5.22% -15.74% -34.14%
NOPAT Growth		 -5.22% -15.74% -34.14%
Net Income Growth		 -5.35% -10.70% -31.23%
EPS Growth		 6.51% 10.43% -22.10%
Operating Cash Flow Growth		 -7.60% -9.42% -47.03%
Free Cash Flow Firm Growth		 -13.10% 3.10% -48.04%
Invested Capital Growth		 8.59% -7.01% 36.42%
Revenue Q/Q Growth		 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 3.53% -1.24% -16.06%
EBIT Q/Q Growth		 0.21% 2.19% -12.40%
NOPAT Q/Q Growth		 0.21% 2.19% -12.40%
Net Income Q/Q Growth		 -0.26% 2.80% -11.27%
EPS Q/Q Growth		 0.00% 8.46% -6.89%
Operating Cash Flow Q/Q Growth		 -9.16% 12.04% -16.39%
Free Cash Flow Firm Q/Q Growth		 -9.12% 23.37% -32.85%
Invested Capital Q/Q Growth		 -3.41% -19.45% 48.10%
Profitability Metrics		 - - -
Gross Margin		 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00%
Tax Burden Percent		 96.97% 95.84% 99.80%
Interest Burden Percent		 97.66% 98.69% 99.10%
Effective Tax Rate		 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -54.14% -50.01% -46.98%
Cash Return on Invested Capital (CROIC)		 -227.30% -201.99% -232.14%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -54.14% -50.01% -46.98%
Return on Equity Simple (ROE_SIMPLE)		 -55.86% -49.86% -45.31%
Net Operating Profit after Tax (NOPAT)		 -191 -182 -157
NOPAT Margin		 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -17.28% -15.79% -16.44%
Return On Investment Capital (ROIC_SIMPLE)		 -41.28% -36.90% -32.07%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -273 -260 -224
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -272 -263 -218
Valuation Ratios		 - - -
Price to Book Value (P/BV)		 2.47 5.49 3.02
Price to Tangible Book Value (P/TBV)		 2.87 6.31 3.49
Price to Revenue (P/Rev)		 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 8.51 27.41 12.01
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00
Leverage & Solvency		 - - -
Debt to Equity		 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00
Financial Leverage		 -0.82 -0.82 -0.83
Leverage Ratio		 1.14 1.14 1.11
Compound Leverage Factor		 1.12 1.12 1.10
Debt to Total Capital		 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00
Altman Z-Score		 6.49 18.79 11.86
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00%
Liquidity Ratios		 - - -
Current Ratio		 9.30 7.80 9.29
Quick Ratio		 9.15 7.69 9.10
Cash Flow Metrics		 - - -
Free Cash Flow to Firm (FCFF)		 -198 -175 -181
Operating Cash Flow to CapEx		 -3,662.02% -1,185.91% -2,131.40%
Free Cash Flow to Firm to Interest Expense		 -105.21 -93.57 -97.25
Operating Cash Flow to Interest Expense		 -111.20 -103.96 -95.67
Operating Cash Flow Less CapEx to Interest Expense		 -114.24 -112.72 -100.16
Efficiency Ratios		 - - -
Asset Turnover		 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00
Capital & Investment Metrics		 - - -
Invested Capital		 91 84 90
Invested Capital Turnover		 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 7.19 -6.31 24
Enterprise Value (EV)		 774 2,295 1,081
Market Capitalization		 1,146 2,702 1,481
Book Value per Share		 $5.08 $5.46 $6.47
Tangible Book Value per Share		 $4.38 $4.75 $5.61
Total Capital		 463 493 490
Total Debt		 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00
Net Debt		 -372 -407 -400
Capital Expenditures (CapEx)		 5.73 16 8.36
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -35 -43 -32
Debt-free Net Working Capital (DFNWC)		 337 330 325
Net Working Capital (NWC)		 337 330 325
Net Nonoperating Expense (NNE)		 68 64 65
Net Nonoperating Obligations (NNO)		 -372 -409 -400
Total Depreciation and Amortization (D&A)		 1.31 -3.07 6.27
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00%
Earnings Adjustments		 - - -
Adjusted Basic Earnings per Share		 ($2.73) ($2.92) ($3.26)
Adjusted Weighted Average Basic Shares Outstanding		 94.81M 84.01M 68.15M
Adjusted Diluted Earnings per Share		 ($2.73) ($2.92) ($3.26)
Adjusted Weighted Average Diluted Shares Outstanding		 94.81M 84.01M 68.15M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 106.63M 90.50M 79.35M
Normalized Net Operating Profit after Tax (NOPAT)		 -191 -182 -157
Normalized NOPAT Margin		 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00%
Debt Service Ratios		 - - -
EBIT to Interest Expense		 -144.86 -138.48 -120.49
NOPAT to Interest Expense		 -101.40 -96.94 -84.34
EBIT Less CapEx to Interest Expense		 -147.90 -147.25 -124.97
NOPAT Less CapEx to Interest Expense		 -104.44 -105.71 -88.83
Payout Ratios		 - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% -0.02%

Quarterly Metrics And Ratios for Rocket Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Rocket Pharmaceuticals' official financial filings.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 9.54% 13.92% -17.07% -6.23% -7.60% -4.50% -3.75% -37.54% -48.76% -78.87% -16.24%
EBIT Growth		 4.43% 0.92% -6.11% -7.21% -8.33% 8.40% -11.87% -26.83% -46.12% -55.83% -17.81%
NOPAT Growth		 4.43% 0.92% -6.11% -7.21% -8.33% 8.40% -11.87% -26.83% -46.12% -55.83% -17.81%
Net Income Growth		 1.16% -1.12% -7.79% -6.00% -6.38% 10.59% -7.17% -20.77% -35.72% -50.80% -15.24%
EPS Growth		 15.15% 0.00% 5.33% 9.76% 9.59% 30.34% 13.79% 1.20% -8.96% -30.88% -10.13%
Operating Cash Flow Growth		 1.87% -60.00% 8.83% -5.81% 1.22% 47.63% -30.30% -30.30% -46.75% -81.06% -59.99%
Free Cash Flow Firm Growth		 53.20% -34.46% 56.38% 20.91% 16.58% 47.52% -137.03% -112.58% -52.95% -99.55% 3.55%
Invested Capital Growth		 -15.48% 8.59% -9.44% 10.30% 12.50% -7.01% 70.97% 44.63% 39.15% 36.42% -5.33%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.26% 10.64% 9.76% -17.22% -1.06% -21.54% 18.12% -18.73% 11.39% -20.67% -8.55%
EBIT Q/Q Growth		 -2.70% 9.69% 5.82% -9.41% -6.47% 3.29% 4.84% -10.55% 9.97% -18.11% -7.89%
NOPAT Q/Q Growth		 -2.70% 9.69% 5.82% -9.41% -6.47% 3.29% 4.84% -10.55% 9.97% -18.11% -7.89%
Net Income Q/Q Growth		 -1.67% 9.58% 4.20% -12.23% -4.01% 3.62% 5.79% -12.63% 12.57% -15.53% -6.17%
EPS Q/Q Growth		 9.68% 12.68% 4.05% -12.12% -6.45% 17.33% 8.54% -12.33% 17.98% -2.30% -4.82%
Operating Cash Flow Q/Q Growth		 -18.85% 9.91% 3.20% 5.33% -93.79% 48.66% -12.34% 11.62% -2.75% -27.73% -12.35%
Free Cash Flow Firm Q/Q Growth		 45.46% -31.67% 36.90% -3.30% -51.22% 57.29% -14.41% -8.95% 1.44% -92.93% -2.61%
Invested Capital Q/Q Growth		 3.38% -3.41% -11.06% -4.84% 30.69% -19.45% 8.32% -2.94% 9.80% 48.10% -8.37%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 96.55% 98.01% 97.30% 96.88% 95.74% 94.80% 96.45% 96.08% 96.02% 98.52% 100.27%
Interest Burden Percent		 98.66% 98.18% 98.77% 97.53% 96.20% 99.46% 98.09% 99.45% 97.68% 98.04% 98.48%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -60.45% -54.14% -59.27% -64.31% -55.38% -50.01% -55.63% -62.86% -54.13% -46.98% -46.75%
Cash Return on Invested Capital (CROIC)		 -167.61% -227.30% -183.66% -197.02% -188.30% -201.99% -278.04% -259.54% -233.82% -232.14% -218.11%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -60.45% -54.14% -59.27% -64.31% -55.38% -50.01% -55.63% -62.86% -54.13% -46.98% -46.75%
Return on Equity Simple (ROE_SIMPLE)		 -62.61% 0.00% -78.26% -65.84% -56.47% 0.00% -46.69% -61.67% -51.70% 0.00% -54.28%
Net Operating Profit after Tax (NOPAT)		 -45 -44 -49 -52 -47 -44 -46 -48 -44 -48 -41
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -5.02% -4.21% -5.39% -6.16% -4.31% -3.80% -4.33% -5.59% -4.19% -4.66% -4.62%
Return On Investment Capital (ROIC_SIMPLE)		 -10.94% -9.47% - - - -8.99% - - - -9.88% -
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -64 -63 -69 -74 -67 -63 -65 -69 -62 -69 -58
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -61 -62 -69 -76 -65 -72 -59 -72 -61 -68 -57
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 1.73 2.47 5.10 5.08 5.50 5.49 3.05 3.97 2.96 3.02 2.87
Price to Tangible Book Value (P/TBV)		 2.04 2.87 6.33 6.10 6.44 6.31 3.46 4.73 3.45 3.49 3.13
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 4.18 8.51 15.35 15.84 18.87 27.41 11.67 13.47 10.11 12.01 12.30
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.76 -0.82 -0.77 -0.74 -0.77 -0.82 -0.82 -0.79 -0.81 -0.83 -0.85
Leverage Ratio		 1.14 1.14 1.14 1.15 1.13 1.14 1.12 1.13 1.11 1.11 1.11
Compound Leverage Factor		 1.12 1.12 1.13 1.12 1.08 1.13 1.10 1.12 1.09 1.09 1.09
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 3.72 7.81 11.69 15.70 22.59 19.94 15.53 14.00 12.81 12.79 10.84
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 9.19 9.30 6.05 7.79 10.47 7.80 13.35 9.09 10.83 9.29 10.31
Quick Ratio		 9.01 9.15 5.89 7.42 10.02 7.69 13.06 8.94 10.61 9.10 10.16
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -28 -51 -39 -61 -60 -38 -89 -78 -71 -72 -38
Operating Cash Flow to CapEx		 -15,326.92% -15,191.59% -3,281.05% -2,788.76% -2,793.91% -631.35% -1,227.67% -1,234.98% -1,909.12% -1,865.50% -8,719.48%
Free Cash Flow to Firm to Interest Expense		 -59.02 -107.98 -82.36 -130.53 -126.36 -80.82 -189.63 -166.09 -152.44 -154.68 -80.69
Operating Cash Flow to Interest Expense		 -118.20 -99.24 -110.62 -114.27 -120.71 -62.42 -121.85 -108.69 -122.99 -119.70 -94.32
Operating Cash Flow Less CapEx to Interest Expense		 -118.97 -99.90 -113.99 -118.37 -125.03 -72.31 -131.78 -117.50 -129.43 -126.12 -95.40
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 94 91 94 106 111 84 104 96 99 90 61
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -17 7.19 -9.81 9.88 12 -6.31 43 30 28 24 -3.42
Enterprise Value (EV)		 393 774 1,445 1,676 2,099 2,295 1,213 1,292 999 1,081 748
Market Capitalization		 711 1,146 1,680 1,955 2,429 2,702 1,650 1,599 1,359 1,481 1,054
Book Value per Share		 $3.87 $5.08 $3.62 $4.24 $4.72 $5.46 $6.72 $5.01 $5.78 $6.47 $5.56
Tangible Book Value per Share		 $3.26 $4.38 $2.92 $3.53 $4.03 $4.75 $5.92 $4.20 $4.97 $5.61 $5.10
Total Capital		 412 463 330 385 442 493 541 403 459 490 367
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -318 -372 -236 -279 -330 -407 -437 -307 -360 -400 -307
Capital Expenditures (CapEx)		 0.36 0.31 1.59 1.93 2.04 4.65 4.66 4.12 3.02 3.00 0.50
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -29 -35 -34 -24 -18 -43 -24 -29 -24 -32 -26
Debt-free Net Working Capital (DFNWC)		 289 337 202 255 312 330 413 278 307 325 281
Net Working Capital (NWC)		 289 337 202 255 312 330 413 278 307 325 281
Net Nonoperating Expense (NNE)		 16 16 18 18 15 15 16 18 15 18 17
Net Nonoperating Obligations (NNO)		 -318 -372 -236 -279 -330 -409 -437 -307 -360 -400 -307
Total Depreciation and Amortization (D&A)		 2.99 1.14 0.54 -2.63 2.25 -8.23 6.59 -3.10 1.67 0.65 1.78
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.56) ($0.62) ($0.71) ($0.74) ($0.66) ($0.62) ($0.75) ($0.82) ($0.73) ($0.89) ($0.87)
Adjusted Weighted Average Basic Shares Outstanding		 110.09M 94.81M 94.16M 93.75M 93.55M 84.01M 82.64M 80.47M 79.45M 68.15M 66.22M
Adjusted Diluted Earnings per Share		 ($0.56) ($0.62) ($0.71) ($0.74) ($0.66) ($0.62) ($0.75) ($0.82) ($0.73) ($0.89) ($0.87)
Adjusted Weighted Average Diluted Shares Outstanding		 110.09M 94.81M 94.16M 93.75M 93.55M 84.01M 82.64M 80.47M 79.45M 68.15M 66.22M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 107.74M 106.63M 91.16M 90.98M 90.78M 90.50M 90.16M 80.53M 80.46M 79.35M 75.68M
Normalized Net Operating Profit after Tax (NOPAT)		 -45 -44 -49 -52 -47 -44 -46 -48 -44 -48 -41
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -136.42 -132.55 -147.40 -156.50 -143.05 -134.64 -139.51 -146.92 -132.89 -147.61 -125.78
NOPAT to Interest Expense		 -95.49 -92.78 -103.18 -109.55 -100.13 -94.25 -97.66 -102.84 -93.03 -103.33 -88.05
EBIT Less CapEx to Interest Expense		 -137.19 -133.20 -150.77 -160.60 -147.37 -144.52 -149.43 -155.72 -139.34 -154.03 -126.86
NOPAT Less CapEx to Interest Expense		 -96.26 -93.44 -106.55 -113.65 -104.45 -104.13 -107.58 -111.64 -99.47 -109.74 -89.13
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -0.02% 0.00%

Frequently Asked Questions About Rocket Pharmaceuticals' Financials

When does Rocket Pharmaceuticals's financial year end?

According to the most recent income statement we have on file, Rocket Pharmaceuticals' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Rocket Pharmaceuticals' net income changed over the last 2 years?

Rocket Pharmaceuticals' net income appears to be on an upward trend, with a most recent value of -$258.75 million in 2024, rising from -$221.86 million in 2022. The previous period was -$245.60 million in 2023.

What is Rocket Pharmaceuticals's operating income?
Rocket Pharmaceuticals's total operating income in 2024 was -$273.21 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $273.21 million
How has Rocket Pharmaceuticals revenue changed over the last 2 years?

Over the last 2 years, Rocket Pharmaceuticals' total revenue changed from $0.00 in 2022 to $0.00 in 2024, a change of 0.0%.

How much debt does Rocket Pharmaceuticals have?

Rocket Pharmaceuticals' total liabilities were at $64.47 million at the end of 2024, a 12.6% decrease from 2023, and a 3.8% increase since 2022.

How much cash does Rocket Pharmaceuticals have?

In the past 2 years, Rocket Pharmaceuticals' cash and equivalents has ranged from $55.90 million in 2023 to $163.64 million in 2024, and is currently $163.64 million as of their latest financial filing in 2024.

How has Rocket Pharmaceuticals' book value per share changed over the last 2 years?

Over the last 2 years, Rocket Pharmaceuticals' book value per share changed from 6.47 in 2022 to 5.08 in 2024, a change of -21.5%.


Related Companies

This page (NASDAQ:RCKTW) was last updated on 5/25/2025 by MarketBeat.com Staff
From Our Partners
Gold Hits New Highs as Global Markets Spiral
When Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...
Premier Gold Co | Sponsored
White House to reset Social Security?
Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...
Altimetry | Sponsored
Buffett’s favorite chart just hit 209% – here’s what that means for gold
A Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...
Golden Portfolio | Sponsored
Is President Trump Lying To You With This?
President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...
Colonial Metals | Sponsored
A grave, grave error.
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...
Porter & Company | Sponsored
Trump’s Bitcoin Reserve is No Accident…
Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...
Crypto 101 Media | Sponsored
This Signal Only Flashes Once Every 4 Years – And It Just Triggered
This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...
Crypto Swap Profits | Sponsored
Massive new energy source found in Utah
NEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...
Stansberry Research | Sponsored